KKR Pays $5.7B Cash for Integer Holdings in Medical Equipment Takeout

KKR agreed to acquire Integer Holdings for $5.7 billion in all-cash, taking private a medical equipment manufacturer whose revenue base runs through cardiac rhythm management, neuromodulation, and portable medical systems. The deal values Integer at a point where surgical component demand is recovering but capital allocation in hospitals remains uneven.

Integer manufactures components and finished devices for implantable systems—pacemakers, defibrillators, neurostimulators—and portable oxygen concentrators. Revenue for fiscal 2025 came in near $1.55 billion, up 6% year-over-year, with gross margin holding at 27.8% despite raw material volatility and labor cost inflation in its Swiss and Mexican facilities. The company services more than 400 OEM customers, including all major cardiac device manufacturers, and holds long-term supply agreements that smooth revenue but compress pricing power. KKR is betting that operational leverage and contract renegotiation under private ownership can push EBITDA margin from the current 18% toward the low twenties within thirty-six months.

This is KKR's second medical equipment platform in eighteen months, following its $3.8 billion take-private of Cotiviti's healthcare analytics arm in early 2025. The firm has allocated roughly $14 billion to healthcare since 2023, with a tilt toward capital-light services and capital-heavy manufacturing where margin expansion is executable through procurement centralization and facility consolidation. Integer's exposure to elective procedures—roughly 40% of revenue ties to non-urgent implants—gives KKR a bet on procedure volume normalization as U.S. hospital admissions for cardiac and neuro cases recover to pre-2024 baselines. The all-cash structure signals confidence that Integer's free cash flow conversion, running near 85%, can service the leverage load without equity dilution or earn-out complexity.

The takeout removes a publicly traded pure-play from the medical component supply chain at a moment when device OEMs are consolidating supplier rosters. Integer's largest customers have been reducing component vendors by 15-20% since 2024, favoring scale players who can meet FDA traceability requirements and absorb cost volatility. Private ownership gives Integer the runway to invest in capacity without quarterly earnings pressure, particularly in its Swiss neuromodulation line, which has been capacity-constrained since mid-2025. KKR's prior work in medical manufacturing—Envision Healthcare, Air Medical—suggests a playbook: cut SKU count by 20-30%, rationalize underperforming facilities, renegotiate raw material contracts, and prepare for a secondary exit to a strategic acquirer or another sponsor within five to seven years.

Operators should watch for two follow-on events. First, whether KKR moves to consolidate Integer with other portfolio assets in adjacent medical component categories, which would create pricing leverage with shared OEM customers. Second, whether device OEMs accelerate their own M&A to bring component manufacturing in-house, a trend that has been building since Abbott and Medtronic both acquired smaller suppliers in 2024 and 2025. If that happens, Integer's valuation as a takeout candidate for a strategic buyer would reset higher, potentially giving KKR an exit inside four years.

The deal closes in Q4 2026, subject to regulatory clearance and Integer shareholder approval. KKR is financing with $2.9 billion in committed debt from JPMorgan and BofA, implying leverage near 5.1x trailing EBITDA, tight but not aggressive for a business with high cash conversion and long-term customer contracts.